JP2015522573A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522573A5 JP2015522573A5 JP2015519000A JP2015519000A JP2015522573A5 JP 2015522573 A5 JP2015522573 A5 JP 2015522573A5 JP 2015519000 A JP2015519000 A JP 2015519000A JP 2015519000 A JP2015519000 A JP 2015519000A JP 2015522573 A5 JP2015522573 A5 JP 2015522573A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- composition according
- composition
- glp
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12174535 | 2012-07-01 | ||
| EP12174535.0 | 2012-07-01 | ||
| US201261694837P | 2012-08-30 | 2012-08-30 | |
| US61/694,837 | 2012-08-30 | ||
| US201261708162P | 2012-10-01 | 2012-10-01 | |
| US61/708,162 | 2012-10-01 | ||
| EP12186781 | 2012-10-01 | ||
| EP12186781.6 | 2012-10-01 | ||
| PCT/EP2013/063004 WO2014005858A1 (en) | 2012-07-01 | 2013-06-21 | Use of long-acting glp-1 peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522573A JP2015522573A (ja) | 2015-08-06 |
| JP2015522573A5 true JP2015522573A5 (https=) | 2016-03-10 |
| JP6059802B2 JP6059802B2 (ja) | 2017-01-11 |
Family
ID=65858459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519000A Active JP6059802B2 (ja) | 2012-07-01 | 2013-06-21 | 長時間作用型ｇｌｐ−１ペプチドの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9764003B2 (https=) |
| EP (3) | EP2866825B1 (https=) |
| JP (1) | JP6059802B2 (https=) |
| AU (3) | AU2013286177B2 (https=) |
| BR (1) | BR112014032938A2 (https=) |
| CA (1) | CA2877056A1 (https=) |
| DK (1) | DK2866825T3 (https=) |
| ES (2) | ES3041720T3 (https=) |
| HR (2) | HRP20200889T1 (https=) |
| HU (2) | HUE072859T2 (https=) |
| MX (3) | MX366405B (https=) |
| PL (2) | PL3689365T3 (https=) |
| PT (1) | PT2866825T (https=) |
| RS (2) | RS67258B1 (https=) |
| RU (2) | RU2018117557A (https=) |
| SI (1) | SI2866825T1 (https=) |
| WO (1) | WO2014005858A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2651398T1 (en) | 2010-12-16 | 2018-04-30 | Novo Nordisk A/S | SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS |
| PL2696687T3 (pl) | 2011-04-12 | 2017-06-30 | Novo Nordisk A/S | Pochodne podwójnie acylowanej GLP-1 |
| HRP20181447T1 (hr) | 2012-03-22 | 2018-11-02 | Novo Nordisk A/S | Pripravci glp-1 peptida i njihova priprava |
| JP6517690B2 (ja) | 2012-06-20 | 2019-05-22 | ノヴォ ノルディスク アー／エス | ペプチド及び送達剤を含む錠剤製剤 |
| EP2866825B1 (en) | 2012-07-01 | 2020-04-08 | Novo Nordisk A/S | Use of long-acting glp-1 peptides |
| KR102272671B1 (ko) | 2013-05-02 | 2021-07-06 | 노보 노르디스크 에이/에스 | Glp-1 화합물의 경구 투여 |
| KR102321242B1 (ko) * | 2014-10-16 | 2021-11-02 | 얀마 파워 테크놀로지 가부시키가이샤 | 작업 차량 |
| GB201621987D0 (en) * | 2016-12-22 | 2017-02-08 | Archer Virgil L See Archer Sheri A Arecor Ltd | Novel composition |
| DE102017106216A1 (de) * | 2017-03-22 | 2018-09-27 | Amw Gmbh | Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung |
| KR102665710B1 (ko) | 2017-08-24 | 2024-05-14 | 노보 노르디스크 에이/에스 | Glp-1 조성물 및 그 용도 |
| CA3078652A1 (en) * | 2017-10-12 | 2019-04-18 | Novo Nordisk A/S | Semaglutide in medical therapy |
| GB201720187D0 (en) * | 2017-12-04 | 2018-01-17 | Imperial Innovations Ltd | Novel Compounds |
| JP6898518B2 (ja) | 2018-02-02 | 2021-07-07 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物 |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| US20210162013A1 (en) * | 2018-08-03 | 2021-06-03 | Brown University | Compositions and methods for improving the bioavailability of glp1 and analogues thereof |
| CN113766930B (zh) * | 2019-02-26 | 2025-07-22 | 特韦斯特生物科学公司 | Glp1受体的变异核酸文库 |
| WO2020180534A1 (en) | 2019-03-01 | 2020-09-10 | President And Fellows Of Harvard College | Methods and compositions for protein delivery |
| IL291876A (en) | 2019-11-06 | 2022-06-01 | Novo Nordisk As | Receptor agonists in glp-1 type dementia |
| EP4086277A4 (en) * | 2019-12-30 | 2024-02-14 | Gan & Lee Pharmaceuticals Co., Ltd. | Long-acting glp-1 compound |
| TW202140058A (zh) | 2020-01-30 | 2021-11-01 | 美商美國禮來大藥廠 | 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途 |
| CN115484935A (zh) | 2020-02-14 | 2022-12-16 | G2G生物公司 | 包括含有glp-1类似物或其药学上可接受的盐的缓释微球的药物组合物 |
| JP7761567B2 (ja) | 2020-02-18 | 2025-10-28 | ノヴォ ノルディスク アー／エス | 医薬製剤 |
| CN112768087A (zh) * | 2020-12-23 | 2021-05-07 | 吉林大学 | 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途 |
| JP2024527528A (ja) * | 2021-06-24 | 2024-07-25 | ギラ セラピューティクス インコーポレイテッド | 満腹感を誘導する、及び代謝障害を治療するための方法及びキット |
| US12514908B2 (en) | 2021-07-05 | 2026-01-06 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| PT4408840T (pt) | 2021-09-27 | 2025-10-07 | Terns Pharmaceuticals Inc | Ácidos benzimidazolocarboxílicos como agonistas de glp-1r |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| AU2022386166A1 (en) | 2021-11-10 | 2024-06-20 | I2O Therapeutics, Inc. | Ionic liquid compositions |
| CN114621339B (zh) * | 2021-12-28 | 2022-09-23 | 北京惠之衡生物科技有限公司 | 一种长效glp-1衍生物 |
| CN119095843A (zh) | 2022-02-23 | 2024-12-06 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| US20230374096A1 (en) * | 2022-05-19 | 2023-11-23 | Vault Bioventures, Inc. | Obesity treatment and prevention methods |
| JP2026502943A (ja) | 2022-12-30 | 2026-01-27 | アルギファルマ エーエス | 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| CN121843690A (zh) | 2023-07-24 | 2026-04-10 | 莱兰斯坦福初级大学评议会 | 用于递送治疗性肽的组合物和方法 |
| WO2025165146A1 (ko) * | 2024-01-29 | 2025-08-07 | 주식회사 티온랩테라퓨틱스 | 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법 |
| KR102930984B1 (ko) * | 2024-01-29 | 2026-02-25 | 주식회사 티온랩테라퓨틱스 | 세마글루타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법 |
| WO2026046328A1 (en) * | 2024-08-30 | 2026-03-05 | Beijing Ql Biopharmaceutical Co., Ltd. | Dosing regimen of glp-1 conjugates |
| CN118845644B (zh) * | 2024-09-27 | 2025-01-17 | 杭州信海医药科技有限公司 | 一种司美格鲁肽注射液的制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| WO2003002136A2 (en) | 2001-06-28 | 2003-01-09 | Novo Nordisk A/S | Stable formulation of modified glp-1 |
| BR122019021416A2 (https=) | 2003-09-19 | 2019-12-21 | ||
| DK3300721T4 (da) | 2003-11-20 | 2025-03-03 | Novo Nordisk As | Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger |
| MX2007005521A (es) | 2004-11-12 | 2007-05-18 | Novo Nordisk As | Formulaciones estables de peptidos insulinotropicos. |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| KR101438839B1 (ko) | 2006-04-14 | 2014-10-02 | 맨카인드 코포레이션 | 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제 |
| CA2677852A1 (en) | 2007-03-20 | 2008-09-25 | Nippon Kayaku Kabushiki Kaisha | Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol |
| US20110144010A1 (en) | 2007-06-01 | 2011-06-16 | Novo Nordisk A/S | Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier |
| US20100292133A1 (en) | 2007-09-05 | 2010-11-18 | Novo Nordisk A/S | Truncated glp-1 derivaties and their therapeutical use |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| PT2373681T (pt) | 2008-12-10 | 2017-04-11 | Glaxosmithkline Llc | Composições farmacêuticas de albiglutida |
| AU2010212823B2 (en) * | 2009-02-13 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| JP6006118B2 (ja) | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アナログ及び誘導体 |
| CN102946875A (zh) * | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| WO2012016419A1 (zh) | 2010-08-06 | 2012-02-09 | 浙江贝达药业有限公司 | Glp-1衍生物及其应用 |
| SI2651398T1 (en) | 2010-12-16 | 2018-04-30 | Novo Nordisk A/S | SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS |
| US20130035281A1 (en) * | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN102718858B (zh) | 2011-03-29 | 2014-07-02 | 天津药物研究院 | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 |
| WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
| CN102229668A (zh) | 2011-06-03 | 2011-11-02 | 浙江贝达药业有限公司 | 一种glp-1衍生物及其应用 |
| WO2012177929A2 (en) | 2011-06-24 | 2012-12-27 | Amylin Pharmaceuticals, Inc. | Methods for treating diabetes with extended release formulations of glp-1 receptor agonists |
| EP2866825B1 (en) | 2012-07-01 | 2020-04-08 | Novo Nordisk A/S | Use of long-acting glp-1 peptides |
-
2013
- 2013-06-21 EP EP13737808.9A patent/EP2866825B1/en not_active Revoked
- 2013-06-21 CA CA2877056A patent/CA2877056A1/en not_active Abandoned
- 2013-06-21 HU HUE20157813A patent/HUE072859T2/hu unknown
- 2013-06-21 JP JP2015519000A patent/JP6059802B2/ja active Active
- 2013-06-21 RS RS20250936A patent/RS67258B1/sr unknown
- 2013-06-21 SI SI201331733T patent/SI2866825T1/sl unknown
- 2013-06-21 PL PL20157813.5T patent/PL3689365T3/pl unknown
- 2013-06-21 RS RS20200684A patent/RS60432B1/sr unknown
- 2013-06-21 HR HRP20200889TT patent/HRP20200889T1/hr unknown
- 2013-06-21 ES ES20157813T patent/ES3041720T3/es active Active
- 2013-06-21 BR BR112014032938A patent/BR112014032938A2/pt not_active Application Discontinuation
- 2013-06-21 EP EP24175788.9A patent/EP4406593A3/en active Pending
- 2013-06-21 ES ES13737808T patent/ES2796839T3/es active Active
- 2013-06-21 RU RU2018117557A patent/RU2018117557A/ru unknown
- 2013-06-21 MX MX2014014946A patent/MX366405B/es active IP Right Grant
- 2013-06-21 US US14/409,493 patent/US9764003B2/en active Active
- 2013-06-21 AU AU2013286177A patent/AU2013286177B2/en active Active
- 2013-06-21 DK DK13737808.9T patent/DK2866825T3/da active
- 2013-06-21 EP EP20157813.5A patent/EP3689365B1/en active Active
- 2013-06-21 PT PT137378089T patent/PT2866825T/pt unknown
- 2013-06-21 PL PL13737808.9T patent/PL2866825T3/pl unknown
- 2013-06-21 HR HRP20251088TT patent/HRP20251088T1/hr unknown
- 2013-06-21 RU RU2015101826A patent/RU2657573C2/ru active
- 2013-06-21 WO PCT/EP2013/063004 patent/WO2014005858A1/en not_active Ceased
- 2013-06-21 MX MX2019008148A patent/MX376058B/es active IP Right Grant
- 2013-06-21 HU HUE13737808A patent/HUE049152T2/hu unknown
-
2014
- 2014-12-05 MX MX2020010693A patent/MX2020010693A/es unknown
-
2017
- 2017-07-21 US US15/656,042 patent/US10335462B2/en active Active
-
2018
- 2018-04-10 AU AU2018202504A patent/AU2018202504B2/en active Active
-
2020
- 2020-04-16 AU AU2020202573A patent/AU2020202573B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522573A5 (https=) | ||
| MX2022004041A (es) | Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos. | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| GB2491328A (en) | Immediate/delayed drug delivery | |
| PH12015501009B1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
| JP2015110588A5 (https=) | ||
| NZ702801A (en) | Treatment of sanfilippo syndrome type b | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| JP2012193216A5 (https=) | ||
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| AU2018256619A1 (en) | Compounds for the treatment of obesity and methods of use thereof | |
| UA111599C2 (uk) | Композиція каспофунгіну | |
| AU2012334804A8 (en) | Modulators of C3a receptors | |
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| HK1225972A1 (zh) | 利用拉喹莫德来延缓亨廷顿氏病的进展 | |
| MY195054A (en) | Pharmaceutical Composition Comprising Mineralocorticoid Receptor Antagonist and use Thereof | |
| WO2011119649A3 (en) | Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs | |
| WO2016072692A3 (ko) | 네크록스를 유효성분으로 함유하는 점막염 예방 또는 치료용 조성물 | |
| UA118656C2 (uk) | Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції | |
| MX2018005345A (es) | Composiciones farmaceuticas de dimetil fumarato. | |
| JP2018043942A5 (https=) | ||
| Sheehy | Ketamine/morphine |